Last10K.com

Genmab As (GMAB) SEC Filing 20-F Annual report for the fiscal year ending Tuesday, December 31, 2019

SEC Filings

GMAB Annual Reports

    20-F Annual Report February 2022
    20-F Annual Report March 2021
  • 20-F Annual Report March 2020

Genmab As

CIK: 1434265 Ticker: GMAB

View differences made from one year to another to evaluate Genmab As's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Genmab As.

Continue

Assess how Genmab As's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Genmab As's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 20-F Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Equity
Consolidated Statements Of Comprehensive Income
Basis Of Presentation
Basis Of Presentation (Policies)
Basis Of Presentation (Tables)
Basis Of Presentation - Collaboration Agreements (Details)
Basis Of Presentation - Ifrs 16 Leasing (Details)
Capital Structure, Financial Risk And Related Items
Capital Structure, Financial Risk And Related Items (Tables)
Capital Structure, Financial Risk And Related Items - Assets And Liabilities In Foreign Currency (Details)
Capital Structure, Financial Risk And Related Items - Capital Management (Details)
Capital Structure, Financial Risk And Related Items - Changes In Share Capital (Details)
Capital Structure, Financial Risk And Related Items - Financial Assets And Liabilities (Details)
Capital Structure, Financial Risk And Related Items - Financial Assets And Liabilities - Narrative (Details)
Capital Structure, Financial Risk And Related Items - Financial Income And Expenses (Details)
Capital Structure, Financial Risk And Related Items - Financial Risk (Details)
Capital Structure, Financial Risk And Related Items - Marketable Securities (Details)
Capital Structure, Financial Risk And Related Items - Marketable Securities Portfolio (Details)
Capital Structure, Financial Risk And Related Items - Maturity Profile Of Our Marketable Securities (Details)
Capital Structure, Financial Risk And Related Items - Restricted Stock Unit Program (Details)
Capital Structure, Financial Risk And Related Items - Rsu Activity (Details)
Capital Structure, Financial Risk And Related Items - Share Capital (Details)
Capital Structure, Financial Risk And Related Items - Treasury Shares (Details)
Capital Structure, Financial Risk And Related Items - Warrant Activity (Details)
Capital Structure, Financial Risk And Related Items - Weighted Average Outstanding Warrants (Details)
Operating Assets And Liabilities
Operating Assets And Liabilities (Tables)
Operating Assets And Liabilities - Accounting Policies And Management Estimates (Details)
Operating Assets And Liabilities - Depreciation (Details)
Operating Assets And Liabilities - Depreciation, Amortization, And Impairments Are Included In The Income Statement (Details)
Operating Assets And Liabilities - Future Minimum Payments Under Our Leases (Details)
Operating Assets And Liabilities - Intangible Assets (Details)
Operating Assets And Liabilities - Leases (Details)
Operating Assets And Liabilities - Other Investments (Details)
Operating Assets And Liabilities - Other Payables (Details)
Operating Assets And Liabilities - Property, Plant And Equipment (Details)
Operating Assets And Liabilities - Provisions (Details)
Operating Assets And Liabilities - Receivables (Details)
Operating Assets And Liabilities - Research Collaboration And License Agreement (Details)
Operating Assets And Liabilities - Total Cash Outflow For Leases (Details)
Other Disclosures
Other Disclosures (Tables)
Other Disclosures - Adjustments To Cash Flow Statement (Details)
Other Disclosures - Collaborations And Technology Licenses (Details)
Other Disclosures - Commitments (Details)
Other Disclosures - Company Overview (Details)
Other Disclosures - Contingent Assets And Contingent Liabilities (Details)
Other Disclosures - Fees To Auditors (Details)
Other Disclosures - Remuneration Of The Board Of Directors And Executive Management (Details)
Other Disclosures - Remuneration To Executive Management (Details)
Other Disclosures - Severance Payments (Details)
Other Disclosures - Share-Based Compensation (Details)
Other Disclosures - Shareholding Requirement For Members Of Executive Management (Details)
Results For The Year
Results For The Year (Details)
Results For The Year (Tables)
Results For The Year - A Reconciliation Of Genmab's Effective Tax (Details)
Results For The Year - Corporate And Deferred Tax (Details)
Results For The Year - Deferred Tax Asset (Details)
Results For The Year - Geographical Areas (Details)
Results For The Year - Result Per Share (Details)
Results For The Year - Staff Costs (Details)
Results For The Year - Valuation Assumptions For Warrants Granted (Details)
Results For The Year - Valuation Assumptions For Warrants Granted Narrative (Details)
Ticker: GMAB
CIK: 1434265
Form Type: 20-F Annual Report
Accession Number: 0001558370-20-003378
Submitted to the SEC: Mon Mar 30 2020 5:12:23 PM EST
Accepted by the SEC: Mon Mar 30 2020
Period: Tuesday, December 31, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/gmab/0001558370-20-003378.htm